MGF (Mechano Growth Factor)

Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor 1 (IGF-1), often referred to as IGF-1Ec. It is produced locally within muscle tissue in response to mechanical loading and damage, and it has been studied for its hypothesized role in the early stages of muscle repair.

MGF is a research-stage compound and is not an FDA-approved medicine. It is important to distinguish MGF from systemic (circulating) IGF-1 and from PEG-MGF, the pegylated analogue engineered for greater stability. Much of what is described about MGF comes from preclinical and laboratory work rather than established clinical use.

Proposed mechanisms for MGF are based largely on cell and animal research and focus on the local muscle response to mechanical stress. High-level themes include:

• Local expression in muscle after mechanical loading or injury, distinct from liver-derived systemic IGF-1
• Hypothesized activation and proliferation of satellite cells, the muscle stem cells involved in repair
• A proposed role in the early phase of tissue remodeling, ahead of the more sustained signaling attributed to systemic IGF-1

How these mechanistic findings translate into meaningful outcomes in humans is an area of ongoing research and remains uncertain.

MGF is not an approved treatment for any condition. It appears primarily in experimental and research contexts exploring muscle biology, repair, and the role of local growth factors.

Because it is a research compound, product quality and evidence strength vary considerably. Any consideration of MGF should be grounded in local regulations and a clear understanding of the difference between exploratory research and established clinical therapies.

MGF is named as its own bullet in S2.3, "Growth factors and growth factor modulators," on the WADA Prohibited List, alongside fibroblast growth factors, hepatocyte growth factor, "insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues," platelet-derived growth factor, VEGF, and "thymosin-β4 and its derivatives e.g. TB-500." The section covers agents affecting muscle, tendon or ligament protein synthesis, vascularisation and regenerative capacity — which is exactly the claim made for MGF, so there is no plausible reading under which it sits outside the list. It is a non-Specified Substance: four-year default sanction.

What is actually in the vial is a separate problem. When a laboratory characterised MGF products bought on the black market, high-resolution mass spectrometry showed they were not human MGF but C-terminal amidated analogues of it — a modification not present in the endogenous protein. The authors reported a diagnostic transition (m/z 717.8 → 431.1) that discriminates the amidated designer form from endogenous MGF (Esposito et al., Rapid Commun Mass Spectrom 2012). Buying a modified analogue does not escape the list — S2.3 extends to substances with similar chemical structure or similar biological effect — and it makes the product easier to prove, since the amidation is a fingerprint the body cannot produce.

A full-length biotechnological MGF has also been characterised for doping-control purposes and implemented into sports drug testing, detectable at 0.25 ng/mL by immunoaffinity purification followed by nanoscale LC-HRMS (Thevis et al., Growth Horm IGF Res 2014).

Possession is enough on its own. Nicholas Pierce, a US ski and snowboard athlete, accepted a three-year sanction beginning 3 October 2024 after admitting he ordered IGF-1 — the parent growth factor of the same S2.3 bullet — for his own use; there was no positive test (USADA announcement).

Because MGF acts through IGF-1-related pathways, discussion of potential risks often draws on what is known about growth factor signaling generally, including theoretical concerns about unregulated cell growth and effects on tissues beyond muscle. Local injection-site reactions and nonspecific symptoms are also discussed.

Robust, long-term human safety data are essentially absent. Careful attention to product sourcing, regulatory guidance, and individual risk factors is important, and high-level summaries cannot substitute for rigorous safety evaluation.

Native MGF is generally described as short-acting and rapidly degraded, which is one reason the pegylated variant (PEG-MGF) was developed to extend its presence in circulation.

This information summarizes commonly discussed research concepts and does not constitute medical advice.

Four different molecules travel under the name "MGF," and the differences are not cosmetic:

• Full-length IGF-1Ec / IGF-1Eb. The complete splice product — mature IGF-1 with its C-terminal extension still attached. In head-to-head cell experiments, this is the form that produces a proliferative response (Fornaro et al., Am J Physiol Endocrinol Metab 2014).

• The 24-amino-acid E-peptide. The C-terminal fragment cleaved away from mature IGF-1, and the thing actually sold as "MGF." It is a short synthetic peptide, not a growth factor with its own receptor.

• C-terminally amidated designer analogues. When black-market MGF products were characterised by high-resolution mass spectrometry, they were not human MGF but amidated variants of it — a modification the body cannot make, which doubles as a detection fingerprint (Esposito et al., Rapid Commun Mass Spectrom 2012).

• PEG-MGF. The same 24-mer with a polyethylene glycol chain attached to slow its clearance.

Amidation and PEGylation are both stability modifications. Neither addresses the more basic problem that the 24-mer's claimed activity has not held up when independent laboratories looked for it.

Research on MGF has examined its expression in loaded muscle, its effects on satellite cells, and its proposed role in repair, mostly in cell and animal models. This work has generated interest in muscle biology but has not established clinical benefit in humans.

Because the evidence base is preclinical and the compound is often confused with systemic IGF-1 and PEG-MGF, claims about MGF should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this peptide, see:

• MGF benefits and areas of interest
• MGF side effects and safety context
• MGF dosing concepts (educational)
• MGF research and evidence overview

What exactly is MGF? It is a 24-amino-acid fragment. The Igf1 gene can be spliced into a form (IGF-1Eb in rodents, IGF-1Ec in humans) whose precursor carries a C-terminal extension; when the 70-amino-acid mature IGF-1 protein is cut free, that leftover 24-residue tail is what was named "mechano-growth factor" (Fornaro et al., Am J Physiol Endocrinol Metab 2014). It is a by-product of IGF-1 processing, not a separate hormone with a receptor of its own.

Does the MGF peptide actually do anything? This is the part vendor pages leave out. Two pharmaceutical companies set out to reproduce the published effects and could not. At concentrations up to 500 ng/mL, MGF peptide failed to increase proliferation of C2C12 cells or primary human skeletal muscle myoblasts, failed to delay myoblast fusion, failed to affect primary mouse muscle stem cells, and failed to activate p-ERK in cardiac myocytes — while mature IGF-1 and full-length IGF-1Eb produced robust responses in the same experiments. The authors concluded that the results "call into question whether there is a physiological role for MGF" (Fornaro et al., 2014). A stabilised version of the peptide was tested too, and also did nothing.

If it does work, how? Not independently. The earlier claim was that the E-peptide acted through some receptor other than IGF-1R. When that was tested directly, both E-peptides increased MAPK signalling, but the effect was abolished by pharmacological IGF-1R blockade, and neither peptide phosphorylated IGF-1R on its own — they appear to work by making the receptor more available to IGF-1 itself (Brisson & Barton, PLoS One 2012). On that reading, MGF is a modulator of IGF-1 signalling at best, not a standalone growth factor.

Is there any human data on MGF? None. No interventional clinical trial administering MGF to people is registered on ClinicalTrials.gov. Every claim about muscle repair, satellite-cell activation, or recovery comes from cell and animal work, and the most rigorous attempt to replicate the cell work was negative. There is no dose, no safety profile, and no efficacy estimate in humans to report.

How is MGF different from IGF-1 and PEG-MGF? IGF-1 is the mature, biologically active 70-amino-acid protein — and an approved medicine as mecasermin. MGF is the 24-residue tail left over when IGF-1 is processed. PEG-MGF is that same tail with a polyethylene glycol chain attached to slow clearance. Only the first of the three has established biological activity and regulatory standing.

Is MGF prohibited in sport? Yes, by name. The 2026 Prohibited List names "Mechano growth factors (MGFs)" as its own bullet under S2.3, alongside IGF-1 and its analogues, thymosin-β4 derivatives, and VEGF (WADA Prohibited List). S2.3 substances are non-Specified and prohibited at all times. Buying a modified analogue does not help: the section covers substances with similar structure or effect, and the amidation found in black-market material is itself a detectable marker (Esposito et al., 2012).